Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | ABL2 | P42684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25407551 | 0.89 | ALK (0.35) | OPRM1OGFRL1OPRD1OPRK1EGFR | |
| SCHEMBL26584990 | 0.87 | OPRM1 (0.41) | OPRM1OGFRL1OPRD1OPRK1CHEK2 | |
| SCHEMBL30528196 | 0.79 | ALK (0.38) | EGFR | |
| SCHEMBL30528203 | 0.78 | USP30 (0.41) | BTKBACE1CTSD | |
| SCHEMBL16895446 | 0.78 | EGFR (0.45) | OPRM1OGFRL1OPRD1OPRK1CHEK2 | |
| SCHEMBL14247494 | 0.75 | USP30 (0.50) | OPRM1OGFRL1OPRD1OPRK1PIK3CA | |
| SCHEMBL572300 | 0.75 | ALK (0.47) | — | |
| SCHEMBL16896153 | 0.75 | EGFR (0.45) | OPRM1OGFRL1OPRD1OPRK1PIK3CA | |
| SCHEMBL16895807 | 0.75 | CYP2C9 (0.44) | OPRM1OGFRL1OPRD1OPRK1CHEK2 | |
| SCHEMBL16896151 | 0.75 | EGFR (0.45) | OPRM1OGFRL1OPRD1OPRK1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295137-A1 | COVALENT EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | OPRM1 2967/4885OGFRL1 328/4885OPRD1 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.